October 13, 2005 -- Despite lackluster public company markets, the private equity sector is humming along quite nicely. Several biotech firms, both private and public, closed financings earlier this week. Almost all were therapeutic companies with compounds in the clinic. Fairly large amounts of money were raised too, on the order of $20-50 million per round. We look at where the money is going...
